Eli Lilly -> Kelonia Therapeutics

Pharmaceutical giant Eli Lilly announced it is acquiring Kelonia Therapeutics, a developer of gene therapies with a particular focus on cancer treatment, in a deal valued at up to $7 billion in cash. Kelonia utilizes AI-powered platforms for developing precise gene therapies, making this one of the largest funded biotech startup purchases in recent years.